Pathobiology of liver fibrosis: a translational success story
暂无分享,去创建一个
[1] T. Sauerbruch,et al. HSC-specific inhibition of Rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects. , 2012, Journal of hepatology.
[2] K. Iwaisako,et al. Origin of myofibroblasts in the fibrotic liver in mice , 2014, Proceedings of the National Academy of Sciences.
[3] L. Galluzzi,et al. Decoding cell death signals in liver inflammation. , 2013, Journal of hepatology.
[4] G. Svegliati-Baroni,et al. Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice , 2014, Hepatology.
[5] L. Marchionni,et al. In Vivo Liver Regeneration Potential of Human Induced Pluripotent Stem Cells from Diverse Origins , 2011, Science Translational Medicine.
[6] Chihiro Morishima,et al. Fibrosis progression in chronic hepatitis C: Morphometric image analysis in the HALT‐C trial , 2009, Hepatology.
[7] A. Baranova,et al. Adipocytokine expression associated with miRNA regulation and diagnosis of NASH in obese patients with NAFLD , 2015, Liver international : official journal of the International Association for the Study of the Liver.
[8] B. Neuschwander‐Tetri,et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. , 2010, The New England journal of medicine.
[9] W. Jeong,et al. Retinoic acid signaling sensitizes hepatic stellate cells to NK cell killing via upregulation of NK cell activating ligand RAE1. , 2007, American journal of physiology. Gastrointestinal and liver physiology.
[10] J. Fallowfield,et al. Liver fibrosis and repair: immune regulation of wound healing in a solid organ , 2014, Nature Reviews Immunology.
[11] R. Evans,et al. A Vitamin D Receptor/SMAD Genomic Circuit Gates Hepatic Fibrotic Response , 2013, Cell.
[12] Christopher K. Glass,et al. Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis , 2012, Proceedings of the National Academy of Sciences.
[13] J. Nattermann,et al. Angiotensin‐II type 1 receptor‐mediated Janus kinase 2 activation induces liver fibrosis , 2014, Hepatology.
[14] G. Kanel,et al. Role of differentiation of liver sinusoidal endothelial cells in progression and regression of hepatic fibrosis in rats. , 2012, Gastroenterology.
[15] D. Brenner,et al. GIV/Girdin is a central hub for pro-fibrogenic signalling networks during liver fibrosis , 2014, Nature Communications.
[16] T. Roskams,et al. Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats , 2014, Hepatology.
[17] O. Pappo,et al. A continuous 13C methacetin breath test for noninvasive assessment of intrahepatic inflammation and fibrosis in patients with chronic HCV infection and normal ALT , 2008, Journal of viral hepatitis.
[18] S. Friedman,et al. Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis , 2004, Gut.
[19] S. Friedman,et al. Hepatic stellate cells and liver fibrosis. , 2013, Comprehensive Physiology.
[20] L. P. Van den Heuvel,et al. Cysteamine: an old drug with new potential. , 2013, Drug discovery today.
[21] Alexander A. Morgan,et al. Computational Repositioning of the Anticonvulsant Topiramate for Inflammatory Bowel Disease , 2011, Science Translational Medicine.
[22] S. Friedman. Liver fibrosis in 2012: Convergent pathways that cause hepatic fibrosis in NASH , 2013, Nature Reviews Gastroenterology &Hepatology.
[23] W. Blaner,et al. Liver X receptors balance lipid stores in hepatic stellate cells through Rab18, a retinoid responsive lipid droplet protein , 2015, Hepatology.
[24] T. Luedde,et al. miR-133a mediates TGF-β-dependent derepression of collagen synthesis in hepatic stellate cells during liver fibrosis. , 2013, Journal of hepatology.
[25] I. Okazaki,et al. Collagenase activity in experimental hepatic fibrosis , 1974, Nature.
[26] Michael Simons,et al. Divergent angiocrine signals from vascular niche balance liver regeneration and fibrosis , 2013, Nature.
[27] M. Bulsara,et al. Image analysis of liver biopsy samples measures fibrosis and predicts clinical outcome. , 2014, Journal of hepatology.
[28] G. Gores,et al. Cathepsin B inactivation attenuates hepatocyte apoptosis and liver damage in steatotic livers after cold ischemia-warm reperfusion injury. , 2005, American journal of physiology. Gastrointestinal and liver physiology.
[29] A. Feldstein,et al. Caspase 1-mediated regulation of fibrogenesis in diet-induced steatohepatitis , 2011, Laboratory Investigation.
[30] Dieter Häussinger,et al. Hepatic stellate cells contribute to progenitor cells and liver regeneration. , 2014, The Journal of clinical investigation.
[31] D. Schuppan,et al. Evolving therapies for liver fibrosis. , 2013, The Journal of clinical investigation.
[32] Ziwei Gu,et al. Acetyl-CoA Carboxylase 2−/− Mutant Mice are Protected against Fatty Liver under High-fat, High-carbohydrate Dietary and de Novo Lipogenic Conditions* , 2012, The Journal of Biological Chemistry.
[33] B. Gao,et al. Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases , 2009, Journal of leukocyte biology.
[34] Jeffrey E. Thatcher,et al. Myocardin-Related Transcription Factor-A Controls Myofibroblast Activation and Fibrosis in Response to Myocardial Infarction , 2010, Circulation research.
[35] S. Friedman,et al. Antifibrotic Activity of Sorafenib in Experimental Hepatic Fibrosis: Refinement of Inhibitory Targets, Dosing, and Window of Efficacy In Vivo , 2012, Digestive Diseases and Sciences.
[36] Julien Vergniol,et al. Relative performances of FibroTest, Fibroscan, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: a step toward the truth in the absence of a gold standard. , 2012, Journal of hepatology.
[37] K. Iwaisako,et al. The nicotinamide adenine dinucleotide phosphate oxidase (NOX) homologues NOX1 and NOX2/gp91phox mediate hepatic fibrosis in mice , 2011, Hepatology.
[38] Douglas A. Simonetto,et al. Vascular endothelial growth factor promotes fibrosis resolution and repair in mice. , 2014, Gastroenterology.
[39] S. Lowe,et al. Senescence of Activated Stellate Cells Limits Liver Fibrosis , 2008, Cell.
[40] Caroline L. Wilson,et al. Multigenerational Epigenetic Adaptation of the Hepatic Wound-Healing Response , 2012, Nature Medicine.
[41] V. de Lédinghen,et al. Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®). , 2014, Journal of hepatology.
[42] B. Neuschwander‐Tetri,et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial , 2015, The Lancet.
[43] A. Burroughs,et al. Collagen proportionate area is superior to other histological methods for sub-classifying cirrhosis and determining prognosis. , 2014, Journal of hepatology.
[44] R. Schwabe,et al. Deactivation of hepatic stellate cells during liver fibrosis resolution in mice. , 2012, Gastroenterology.
[45] A. Shen,et al. Myocardin related transcription factor A programs epigenetic activation of hepatic stellate cells. , 2015, Journal of hepatology.
[46] L. DeLeve,et al. Liver sinusoidal endothelial cells and liver regeneration. , 2013, The Journal of clinical investigation.
[47] Lakshmi A Devi,et al. AT1R–CB1R heteromerization reveals a new mechanism for the pathogenic properties of angiotensin II , 2011, The EMBO journal.
[48] C. Gandhi,et al. miR-122 regulates collagen production via targeting hepatic stellate cells and suppressing P4HA1 expression. , 2013, Journal of hepatology.
[49] L. J. Lee,et al. Epigenetic regulation of connective tissue growth factor by MicroRNA‐214 delivery in exosomes from mouse or human hepatic stellate cells , 2014, Hepatology.
[50] L. Adorini,et al. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. , 2012, Drug discovery today.
[51] F. Tacke,et al. Roles for chemokines in liver disease. , 2014, Gastroenterology.
[52] I. N. Crispe,et al. Immune tolerance in liver disease , 2014, Hepatology.
[53] S. Friedman,et al. Scraping fibrosis: Expressway to the core of fibrosis , 2011, Nature Medicine.
[54] D. Mann. Epigenetics in liver disease , 2014, Hepatology.
[55] C. Bocca,et al. Cellular and molecular mechanisms in liver fibrogenesis. , 2014, Archives of biochemistry and biophysics.
[56] S. Forbes,et al. Systematic review: the effects of autologous stem cell therapy for patients with liver disease , 2014, Alimentary pharmacology & therapeutics.
[57] Ramon Planas,et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. , 2007, Gastroenterology.
[58] D. Hum,et al. Hepatoprotective effects of the dual peroxisome proliferator‐activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis , 2013, Hepatology.
[59] Lan Wei,et al. Molecular MR imaging of liver fibrosis: a feasibility study using rat and mouse models. , 2012, Journal of hepatology.
[60] S. Friedman,et al. Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C? , 2014, Antiviral research.
[61] J. Hoefs,et al. Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: Results from the hepatitis C antiviral long‐term treatment against cirrhosis trial , 2012, Hepatology.
[62] D. Mann,et al. Clinical evidence for the regression of liver fibrosis. , 2012, Journal of hepatology.
[63] N. Rosenthal,et al. Preparing the ground for tissue regeneration: from mechanism to therapy , 2014, Nature Medicine.
[64] P. Tontonoz,et al. Liver X receptor signaling is a determinant of stellate cell activation and susceptibility to fibrotic liver disease. , 2011, Gastroenterology.
[65] F. Bellanti,et al. Free radical biology for medicine: learning from nonalcoholic fatty liver disease. , 2013, Free radical biology & medicine.
[66] R. Perez-Tamayo. Cirrhosis of the liver: a reversible disease? , 1979, Pathology annual.
[67] J. Pawlotsky,et al. Liver stiffness diminishes with antiviral response in chronic hepatitis C , 2011, Alimentary pharmacology & therapeutics.
[68] K. Yoshizato,et al. Down‐regulation of cyclin E1 expression by microrna‐195 accounts for interferon‐β‐induced inhibition of hepatic stellate cell proliferation , 2011, Journal of cellular physiology.
[69] S. Friedman,et al. A novel murine model to deplete hepatic stellate cells uncovers their role in amplifying liver damage in mice , 2013, Hepatology.
[70] David Hecht,et al. Oral IDN‐6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C , 2007, Hepatology.
[71] S. Forbes,et al. Links between hepatic fibrosis, ductular reaction, and progenitor cell expansion. , 2014, Gastroenterology.
[72] S. Robson,et al. Purinergic Signaling in Liver Disease , 2014, Digestive Diseases.
[73] K. Kodys,et al. IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice. , 2012, The Journal of clinical investigation.
[74] R. Schwabe,et al. Gene expression profiles during hepatic stellate cell activation in culture and in vivo. , 2007, Gastroenterology.
[75] R. Schwabe,et al. Absence of hepatic stellate cell retinoid lipid droplets does not enhance hepatic fibrosis but decreases hepatic carcinogenesis , 2011, Gut.
[76] S. Friedman,et al. Regression of Fibrosis and Reversal of Cirrhosis in Rats by Galectin Inhibitors in Thioacetamide-Induced Liver Disease , 2013, PloS one.
[77] Amitabh Chandra,et al. Ensuring the fiscal sustainability of health care reform. , 2010, The New England journal of medicine.
[78] A. Wree,et al. From NAFLD to NASH to cirrhosis—new insights into disease mechanisms , 2013, Nature Reviews Gastroenterology &Hepatology.
[79] C. Piantadosi,et al. Hedgehog controls hepatic stellate cell fate by regulating metabolism. , 2012, Gastroenterology.
[80] G. Karaca,et al. Smoothened is a master regulator of adult liver repair. , 2013, The Journal of clinical investigation.
[81] S. Friedman,et al. Autophagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues. , 2012, Gastroenterology.
[82] P. Jares,et al. Ghrelin attenuates hepatocellular injury and liver fibrogenesis in rodents and influences fibrosis progression in humans , 2010, Hepatology.
[83] M. Layne,et al. Myocardin-related Transcription Factor-A Complexes Activate Type I Collagen Expression in Lung Fibroblasts* , 2011, The Journal of Biological Chemistry.
[84] D. Schuppan,et al. Novel engineered targeted interferon‐gamma blocks hepatic fibrogenesis in mice , 2011, Hepatology.
[85] M. Robson,et al. Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease , 2014, Journal of hepatology.
[86] J. Fallowfield,et al. Edinburgh Research Explorer Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis Differential Ly-6C expression identi fi es the recruited macrophage phenotype, which orchestrates the regression of murine liver fi brosis , 2022 .
[87] D. Hume,et al. Macrophage therapy for murine liver fibrosis recruits host effector cells improving fibrosis, regeneration, and function , 2011, Hepatology.
[88] S. Friedman,et al. Contributions of metabolic dysregulation and inflammation to nonalcoholic steatohepatitis, hepatic fibrosis, and cancer , 2014, Current opinion in oncology.
[89] T. Hibi,et al. Free cholesterol accumulation in hepatic stellate cells: Mechanism of liver fibrosis aggravation in nonalcoholic steatohepatitis in mice , 2014, Hepatology.
[90] S. Werner,et al. Endoplasmic reticulum stress induces fibrogenic activity in hepatic stellate cells through autophagy. , 2013, Journal of hepatology.
[91] M. Braddock,et al. The role of fibroblast growth factor 21 in the pathogenesis of liver disease: a novel predictor and therapeutic target , 2014, Expert opinion on therapeutic targets.
[92] W. Jeong,et al. Alcohol dehydrogenase III exacerbates liver fibrosis by enhancing stellate cell activation and suppressing natural killer cells in mice , 2014, Hepatology.
[93] Taotao Ma,et al. DNMT1-mediated PTEN hypermethylation confers hepatic stellate cell activation and liver fibrogenesis in rats. , 2012, Toxicology and applied pharmacology.
[94] J. Duffield,et al. PRM-151 (recombinant human serum amyloid P/pentraxin 2) for the treatment of fibrosis. , 2010, Drug news & perspectives.
[95] J. Sicklick,et al. Sustained activation of Rac1 in hepatic stellate cells promotes liver injury and fibrosis in mice , 2006, Hepatology.
[96] J. Sninsky,et al. Role of a cirrhosis risk score for the early prediction of fibrosis progression in hepatitis C patients with minimal liver disease. , 2009, Journal of hepatology.
[97] John P Iredale,et al. Elastin accumulation is regulated at the level of degradation by macrophage metalloelastase (MMP‐12) during experimental liver fibrosis , 2012, Hepatology.
[98] H. Koga,et al. Adiponectin suppresses endoplasmic reticulum stress in nonalcoholic steatohepatitis. , 2011, Experimental and therapeutic medicine.
[99] Lan Wei,et al. Molecular MRI of collagen to diagnose and stage liver fibrosis. , 2013, Journal of hepatology.
[100] Junfeng Zhang,et al. The Autoregulatory Feedback Loop of MicroRNA-21/Programmed Cell Death Protein 4/Activation Protein-1 (MiR-21/PDCD4/AP-1) as a Driving Force for Hepatic Fibrosis Development* , 2013, The Journal of Biological Chemistry.
[101] D. Griggs,et al. Selective αv integrin depletion identifies a core, targetable molecular pathway that regulates fibrosis across solid organs , 2013, Nature Network Boston.
[102] V. Paradis,et al. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis , 2012, Hepatology.
[103] Jaw-Town Lin,et al. Improvement of Nonalcoholic Fatty Liver Disease After Bariatric Surgery in Morbidly Obese Chinese Patients , 2012, Obesity Surgery.
[104] W. Mehal. The Gordian Knot of dysbiosis, obesity and NAFLD , 2013, Nature Reviews Gastroenterology &Hepatology.
[105] John F. Flaherty,et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study , 2013, The Lancet.
[106] Tse-Ching Chen,et al. Imatinib Mesylate Improves Liver Regeneration and Attenuates Liver Fibrogenesis in CCL4-Treated Mice , 2012, Journal of Gastrointestinal Surgery.
[107] V. Ratziu. Starting the battle to control non-alcoholic steatohepatitis , 2015, The Lancet.
[108] Sushant Bhatnagar,et al. Fibroblast Growth Factor-19, a Novel Factor That Inhibits Hepatic Fatty Acid Synthesis* , 2009, Journal of Biological Chemistry.
[109] J. Fallowfield,et al. Using non-invasive biomarkers to identify hepatic fibrosis in people with type 2 diabetes mellitus: the Edinburgh type 2 diabetes study. , 2014, Journal of hepatology.
[110] A. Mallat,et al. Cannabinoid signaling and liver therapeutics. , 2013, Journal of hepatology.
[111] R. Schwabe,et al. Fate-tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its etiology , 2013, Nature Communications.
[112] D. Lorrain,et al. A novel, orally active LPA1 receptor antagonist inhibits lung fibrosis in the mouse bleomycin model , 2010, British journal of pharmacology.
[113] Qingjian Wang,et al. Cooperative interaction of CTGF and TGF-β in animal models of fibrotic disease , 2011, Fibrogenesis & tissue repair.
[114] M. Ebrahimkhani,et al. Stimulating healthy tissue regeneration by targeting the 5-HT2B receptor in chronic liver disease , 2011, Nature Medicine.
[115] Tsutomu Masaki,et al. Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats. , 2005, American journal of physiology. Gastrointestinal and liver physiology.
[116] T. Luedde,et al. Pharmacological inhibition of the chemokine C‐C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly‐6C+ macrophage infiltration in mice , 2014, Hepatology.
[117] M. Manns,et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. , 2012, JAMA.
[118] K. Yoshizato,et al. MicroRNA-221/222 upregulation indicates the activation of stellate cells and the progression of liver fibrosis , 2012, Gut.
[119] S. Reif,et al. Amplified Inhibition of Stellate Cell Activation Pathways by PPAR-γ, RAR and RXR Agonists , 2013, PloS one.
[120] Alexander A. Morgan,et al. Supplementary Materials for Computational Repositioning of the Anticonvulsant Topiramate for Inflammatory Bowel Disease , 2011 .
[121] L. Marín-Gómez,et al. GATA4 loss in the septum transversum mesenchyme promotes liver fibrosis in mice , 2014, Hepatology.
[122] D. Thabut,et al. Origins and functions of liver myofibroblasts. , 2013, Biochimica et biophysica acta.
[123] D. Mann,et al. NF-kappaB signalling: embracing complexity to achieve translation. , 2010, Journal of hepatology.
[124] Derek Marshall,et al. Allosteric inhibition of lysyl oxidase–like-2 impedes the development of a pathologic microenvironment , 2010, Nature Medicine.
[125] B. Gao,et al. Natural killer and natural killer T cells in liver fibrosis. , 2013, Biochimica et biophysica acta.
[126] P. Weinreb,et al. Inhibition of Integrin αvβ6, an Activator of Latent Transforming Growth Factor-β, Prevents Radiation-induced Lung Fibrosis , 2008 .
[127] F. Ginhoux,et al. Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis , 2009, Hepatology.
[128] K. Zatloukal,et al. Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts. , 2009, The American journal of pathology.
[129] Christopher J. Parsons,et al. Antifibrotic effects of a tissue inhibitor of metalloproteinase‐1 antibody on established liver fibrosis in rats , 2004, Hepatology.
[130] L. DeLeve. Liver sinusoidal endothelial cells in hepatic fibrosis , 2015, Hepatology.
[131] S. Mudaliar,et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. , 2013, Gastroenterology.
[132] Frank Tacke,et al. Macrophage heterogeneity in liver injury and fibrosis. , 2014, Journal of hepatology.
[133] H. Bonkovsky,et al. Novel role of nuclear receptor rev‐erbα in hepatic stellate cell activation: Potential therapeutic target for liver injury , 2014, Hepatology.
[134] A. Miyajima,et al. Hepatic Stellate Cell-derived Delta-like Homolog 1 (DLK1) Protein in Liver Regeneration* , 2012, The Journal of Biological Chemistry.
[135] S. Friedman,et al. Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis , 2010, Hepatology.
[136] T. Luedde,et al. Micro‐RNA profiling reveals a role for miR‐29 in human and murine liver fibrosis , 2011, Hepatology.
[137] Kristian Helin,et al. Chromatin proteins and modifications as drug targets , 2013, Nature.